#biotech

#biotech

EFFECTOR Therapeutics, a biotech company focusing on cancer research, is shutting down after failing to bring a product to market despite raising significant funds.

HERVolution secures $11.7 million Series A funding to advance HERV-targeting immunotherapies.

Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.

Amazon reports strong earnings driven by cloud and advertising growth.

Atlassian sees major stock surge after exceeding earnings expectations.

Intel beats earnings and revenue estimates, boosting investor confidence.

Abbott's stock rises after jury ruling in a liability case.

Insider buying signals confidence in stock performance, especially during uncertain market conditions.

Berkshire Hathaway continues to show strong investment activity in key sectors, such as media and biotech.

Eli Lilly's stock has risen dramatically, but future estimates depend on revenue projections and strategic partnerships.

AI is rapidly transforming biotech, with companies like Cradle leading the charge in protein design and development.

Olivia Wilde launches Proximity Ventures, targeting early and growth-stage investments in consumer and enterprise sectors.

Cradle raised $73 million to enhance its AI platform for protein development, aiming to optimize DNA sequences and scale operations.

Rotterdam-based Pan Cancer T secured €4.25M in seed extension, advancing T cell therapies for solid cancers, with support from new and existing investors.

Instadeep has advanced its AI capabilities significantly while aligning with BioNTech's therapeutic goals post-acquisition.

AI is revolutionizing protein design, enabling the creation of sustainable alternatives for various products.

Arzeda leverages proprietary data and advanced AI techniques to transition from research to commercial application.

SoftBank Group and Tempus form joint venture in Japan to develop AI-powered personalized medical services, starting with oncology.

Archon Biosciences aims to revolutionize antibody treatments through innovative protein 'cages' that improve drug binding and efficacy.

Cradle has raised $73M in Series B funding to expand AI capabilities in protein engineering, totaling over $100M raised to date.

NYC Tech is witnessing significant startup funding, indicating a robust entrepreneurial ecosystem.

Diverse NYC startup fundings and events include Gameto's $33M biotech raise, Authentic Insurance's $11M, Matter Bio's $7M, and Clasp's $6.4M funding.

Prolific Machines has developed a bioreactor using light to control cell growth, aiming to revolutionize manufacturing of cultivated meat and medicine.

Visibuilt raises €1.3 million to develop visiBIT, a sustainable binder that could replace traditional bitumen in asphalt production and reduce CO2 emissions.

Traditional lab designs may inhibit research by not accommodating the diverse needs of neurodivergent scientists.

This week saw startups securing significant funding in tech, energy, and biotech sectors, focusing on innovative solutions and sustainable practices.

Gilead Sciences is reducing its workforce amid a strategic reallocation of resources for future product launches.

Genentech's recent layoffs of 93 employees are part of ongoing workforce evaluations due to unmet research goals and restructuring needs.

Investors are shifting focus to growth stocks as interest rates decline, with a mix of established companies and biotech options leading the pack.

Penny stocks can yield high returns but involve significant risk; focus on biotech for multiple catalysts.

Investing in biotech penny stocks offers more potential due to their development timelines and regulatory advancements.

AI is transforming drug discovery, particularly for cardiovascular diseases.

CardiaTec raised $6.5 million to enhance cardiovascular disease treatments through AI.

CVDs cause 17.9 million deaths annually, highlighting a major health crisis.

Generare raised €5 million to enhance its scalable methods for discovering natural compounds for drug development.

The merger between Recursion and Exscientia aims to combine their expertise to accelerate drug design and development.

Biotech investors tap into generative AI for drug discovery.

Generare secures €5M funding to enhance biotechnology for drug discovery by leveraging microbial DNA.

Triveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.

NADMED secures €3.5 million in funding to expand its health diagnostics technology, focused on measuring crucial metabolites associated with age-related diseases.

TechCrunch launching interview series on AI-focused women academics.

Francine Bennett involved in AI work in biotech and data science.

Machine learning is crucial in safety, security, biotech, and pharma industries at ODSC East 2024.